EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib in patients with extensive vitiligo in a phase 2, randomized, double-blinded, dose-ranging, placebo-controlled study

Amit G Pandya, Khaled Ezzedine, Thierry Passeron, Nanja van Geel, Kurt Brown, Leandro L Santos, Lois Erskine, Kofi Wagya, Andrew Blauvelt

Journal of the American Academy of Dermatology · 2025-10 · 93 (4) · 946-955

DOI: 10.1016/j.jaad.2025.06.027 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of the American Academy of Dermatology, 2025-10. Verfasst von Amit G Pandya und 8 weiteren Autor:innen. Beteiligte Einrichtung: Palo Alto Foundation Medical Group, Sunnyvale, California. Electronic address: amit.pandya@sbcglobal.net. Hauptthemen laut MEDLINE: Vitiligo, Janus Kinase 1, Protein Kinase Inhibitors, Quinolines. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Incyte Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: No repigmentation treatments are approved for vitiligo affecting > 10% body surface area. OBJECTIVE: To assess efficacy and safety of povorcitinib (oral, selective Janus kinase 1 inhibitor) in extensive nonsegmental vitiligo. METHODS: This double-blinded, placebo-controlled, dose-ranging phase 2 study (NCT04818346) randomized adult patients 1:1:1:1 to once-daily povorcitinib 15, 45, or 75 mg or placebo for 24 weeks. Subsequently, patients received povorcitinib 45 mg (initially randomized to 45 mg) or 75 mg (initially randomized to placebo, 15, or 75 mg) until week 52, followed by 24-week post-treatment follow-up. Primary endpoint was percentage change from baseline in total Vitiligo Area Scoring Index (T-VASI) at week 24. RESULTS: Of 171 patients (mean total body surface area/T-VASI, 28.2%/25.5) randomized, 82.5% completed the 24-week treatment. At week 24, povorcitinib significantly improved T-VASI from baseline (15 mg, 19.1%; 45 mg, 17.8%; 75 mg, 15.7%) versus placebo (-2.3%; least squares mean povorcitinib vs placebo, P < .01). Continuous improvement was observed through week 52. Incidence of grade ≥ 3 treatment-emergent adverse events was similar across treatment groups, with no new safety signals. LIMITATIONS: Limited demographic diversity. CONCLUSION: Povorcitinib demonstrated substantial total body and facial repigmentation in adult patients with extensive nonsegmental vitiligo and was generally well tolerated through 52 weeks of treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VitiligoJanus Kinase 1Protein Kinase InhibitorsQuinolinesHumansFemaleDouble-Blind MethodMaleAdultMiddle AgedTreatment OutcomeDose-Response Relationship, DrugAdministration, OralSeverity of Illness IndexYoung AdultAgedBenzimidazolesQuinolones

Stichwörter der Autor:innen

F-VASIINCB054707JAK/STAT signalingJAK1 inhibitorT-VASIclinical trialdouble-blindefficacyoral administrationplacebo-controlledpovorcitinibrandomizedsafetyskin repigmentationvitiligo

Substanzen

Janus Kinase 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-oneProtein Kinase InhibitorsQuinolinesJAK1 protein, humanBenzimidazolesQuinolones

Autor:innen und Institutionen

  • Palo Alto Foundation Medical Group, Sunnyvale, California. Electronic address: amit.pandya@sbcglobal.net.
  • Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris (AP-HP), Créteil, France; EpiDermE, Epidemiology in Dermatology and Evaluation of Therapeutics, Paris Est Créteil University UPEC, Cré…
  • Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Archet 2 Hospital, Nice, France; INSERM U1065, C3M, Université Côte d'Azur, Nice, France.
  • Ghent University Hospital, Ghent, Belgium.
  • Incyte Corporation, Wilmington, Delaware.
  • Blauvelt Consulting, LLC, Annapolis, Maryland.

Förderung

  • Incyte Corporation

Zitieren

APA

Pandya, A. G., Ezzedine, K., Passeron, T., van Geel, N., Brown, K., Santos, L. L., Erskine, L., Wagya, K., & Blauvelt, A. (2025). Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib in patients with extensive vitiligo in a phase 2, randomized, double-blinded, dose-ranging, placebo-controlled study. Journal of the American Academy of Dermatology, 93(4), 946-955. https://doi.org/10.1016/j.jaad.2025.06.027

Vancouver

Pandya AG, Ezzedine K, Passeron T, van Geel N, Brown K, Santos LL, et al. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib in patients with extensive vitiligo in a phase 2, randomized, double-blinded, dose-ranging, placebo-controlled study. Journal of the American Academy of Dermatology. 2025;93(4):946-955. doi:10.1016/j.jaad.2025.06.027

BibTeX
@article{Pandya2025,
  author = {Pandya, Amit G and Ezzedine, Khaled and Passeron, Thierry and van Geel, Nanja and Brown, Kurt and Santos, Leandro L and Erskine, Lois and Wagya, Kofi and Blauvelt, Andrew},
  title = {Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib in patients with extensive vitiligo in a phase 2, randomized, double-blinded, dose-ranging, placebo-controlled study},
  journal = {Journal of the American Academy of Dermatology},
  year = {2025},
  volume = {93},
  number = {4},
  pages = {946--955},
  doi = {10.1016/j.jaad.2025.06.027}
}
Kostenlos starten →